PolyPid Operating Income Over Time
| PYPD Stock | USD 4.87 0.29 6.33% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out PolyPid Performance and PolyPid Correlation. Will Biotechnology sector continue expanding? Could PolyPid diversify its offerings? Factors like these will boost the valuation of PolyPid. Anticipated expansion of PolyPid directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every PolyPid data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of PolyPid is measured differently than its book value, which is the value of PolyPid that is recorded on the company's balance sheet. Investors also form their own opinion of PolyPid's value that differs from its market value or its book value, called intrinsic value, which is PolyPid's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because PolyPid's market value can be influenced by many factors that don't directly affect PolyPid's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between PolyPid's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PolyPid should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, PolyPid's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare PolyPid and related stocks such as Annovis Bio, Reviva Pharmaceuticals, and Bioatla Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANVS | (354.9 K) | (1.8 M) | (1.8 M) | (682.4 K) | (682.4 K) | (682.4 K) | (682.4 K) | (682.4 K) | (713.9 K) | (1.6 M) | (6.6 M) | (14.5 M) | (25.5 M) | (45 M) | (26.7 M) | (24 M) | (22.8 M) |
| RVPH | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (376.9 K) | (2.4 M) | (10.1 M) | (24.3 M) | (39.5 M) | (30.8 M) | (27.7 M) | (26.3 M) |
| BCAB | (28.2 M) | (28.2 M) | (28.2 M) | (28.2 M) | (28.2 M) | (28.2 M) | (28.2 M) | (28.2 M) | (28.2 M) | (28.3 M) | (30.1 M) | (96.4 M) | (108.1 M) | (129.7 M) | (73.9 M) | (66.5 M) | (69.9 M) |
| EVAX | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (11.4 M) | (16.6 M) | (25.8 M) | (25.3 M) | (22.2 M) | (14.7 M) | (13.3 M) | (13.9 M) |
| CELU | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (264.1 M) | (151.9 M) | (109.1 M) | (25.6 M) | (76.5 M) | (38.4 M) | (44.1 M) | (46.3 M) |
| MAIA | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (7 M) | (7.8 M) | (16.2 M) | (20.2 M) | (17 M) | (15.3 M) | (16 M) |
| VERU | 900 K | 10.9 M | 9.8 M | 3.9 M | 6.6 M | 3 M | (8.5 M) | (20.9 M) | (6.4 M) | (14.7 M) | 13 M | (83.2 M) | (93.8 M) | (36.9 M) | 9.1 M | 8.2 M | 8.6 M |
| ATNM | (17.5 K) | (10 K) | (7.9 M) | (6.6 M) | (22.5 M) | (24.8 M) | (26.8 M) | (26.9 M) | (23.8 M) | (22.1 M) | (22.4 M) | (25 M) | (34.1 M) | (51.9 M) | (42.1 M) | (37.9 M) | (36 M) |
| BTAI | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (2.1 M) | (4.5 M) | (20 M) | (33.6 M) | (82.3 M) | (106.9 M) | (159.6 M) | (171.8 M) | (67.2 M) | (60.5 M) | (63.5 M) |
| PDSB | (4.7 M) | (4.7 M) | (4.7 M) | (6.5 M) | (13.2 M) | (26.5 M) | (39.5 M) | (52 M) | (43.1 M) | (15.5 M) | (14.9 M) | (21.4 M) | (41.7 M) | (43 M) | (36.3 M) | (32.7 M) | (34.3 M) |
PolyPid and related stocks such as Annovis Bio, Reviva Pharmaceuticals, and Bioatla Operating Income description
Operating Income is the amount of profit realized from PolyPid operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of PolyPid is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| PolyPid | PYPD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 18 Hasivim Street, |
| Exchange | NASDAQ Exchange |
USD 4.87
Check out PolyPid Performance and PolyPid Correlation. For information on how to trade PolyPid Stock refer to our How to Trade PolyPid Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
PolyPid technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.